الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 159 |  |  |
| | | from | 159 | | |
Abstract
Our study aim is to evaluate the effect of intravenous administration of MSCs on the hearts of rats with metabolic syndrome complicated with cardiomyopathy .
We begin our study on sixty rats (20 control and 40 tested animals), the tested animals were fed on high fat diet for 16 months. Fourteen months after high fat diet only 30 rats were alive of the tested animals; 16 rats were injected with MScs intravenously and the remaining 14 rats were injected with the vehicle only. Two months after injection (at the end of the study) we only had 46 animals; 18 (healthy or control group), 14 metabolic syndrome complicated with cardiomyopathy (obesity induced diabetic cardiomyopathy group), and 14 (MScs injected group)
Two months following MSC administration the following parameters will be evaluated as: Blood pressure, blood glucose, glycated hemoglobin, insulin, triglyceride and cholesterol, Gene expression of p300, atrial natriuretic peptide (ANP) and myocytes enhancer factor 2 (MEF2A and MEF2C).
At the end of the study rats were sacrificed by cut throat and dissected to expose the hearts that were fixed in 10% formalin. Sections from the hearts were stained by (H&E) and Masson’s trichrome.
Blood glucose, cholesterol, triglyceride, glycated hemoglobin were significantly decreased in MScs injected group when compared to non injected group of rats with metabolic syndrome complicated with cardiomyopathy .
. Gene expression of p300, atrial natriuretic peptide (ANP) and myocytes enhancer factor 2 (MEF2A and MEF2C) by real time PCR as molecular markers of cardiac hypertrophy weresignificantly decreased.
Cardiomyocyte hypertrophy and number of inflammatory cells were significantly decreased. Also fibrosis decreased .
Conclusion
In conclusion, MScs ingection decrease blood glucose, glycated hemoglobin, triglyceride and cholesterol, Gene expression of p300, atrial natriuretic peptide (ANP) and myocytes enhancer factor 2 (MEF2A and MEF2C), cardiomyocyte hypertrophy, number of inflammatory cells and fibrosis in rats with metabolic syndrome complicated with cardiomyopathy.so can be used in patients with cardiomyopathy as anew line of treatment.